



# SUVEN Life Sciences

## Communication to investors June 2012

14-Aug-12

*2012-13 Q1 results*



# Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

# FINANCIAL QUICK VIEW

## Quarter 1 – June 2012



• Growth in revenue	58.47%
• Growth in PAT	136.94%
• Growth in EBIDTA	157.95%
• Growth in Pre-R&D EBIDTA	75.91%
• Increase in R&D costs	16.96%
• R&D cost on revenue	12.31%

# MAJOR PROFITABILITY RATIOS




	Q1 June 12	Q1 June 11
PAT to Income	11.21%	7.50%
EBIDTA to Income	19.51%	11.99%
Cash Flow to Income	13.79%	10.59%
Pre-R&D EBITDA to Income	31.82%	28.66%

14-Aug-12

2012-13 Q1 results



# INCOME COMPARISON




14-Aug-12

2012-13 Q1 results



# PROFIT COMPARISON




14-Aug-12

2012-13 Q1 results




# EBIDTA COMPARISON



14-Aug-12

2012-13 Q1 results

# R & D – EXPENDITURE




14-Aug-12

2012-13 Q1 results



# PRE-R&D EBIDTA




14-Aug-12

2012-13 Q1 results



# PRE-R&D CASHFLOW



14-Aug-12

2012-13 Q1 results



# Updates for the quarter

- **During the quarter there were major qualitative achievements with the grant of 8 product patents to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia**
- **The Hon'ble High Court of Andhra Pradesh has sanctioned the Scheme of Amalgamation of Suven Nishtaa Pharma Private Limited with Suven Life Sciences Limited and order of High Court has been filed with Registrar of Companies, Andhra Pradesh, Hyderabad**
- **The Board has recommended a Dividend of Re 0.30 per share (30% of face value of Rs.1.00 each) for the accounting year 2011-12 subject to the approval in AGM**

14-Aug-12

2012-13 Q1 results